“…Also, high levels of eIF3b have been detected in several tumors, such as hepatocellular carcinoma (HCC) 46 , osteosarcoma 47 , clear cell renal cell carcinoma (ccRCC) 48 , bladder cancer 49 , prostate cancer 49 , esophageal squamous cell carcinoma (ESCC) 50 , glioblastoma 51 , colon cancer 52 , breast cancer 53 and gastric cancer 54 . In ccRCC, high expression of eIF3b is not only associated with an aggressive tumor phenotype, but also is an independent predictor of patient prognosis 48 . Overexpression of eIF3b in ESCC was found to be associated with lymph node metastasis, tumor depth, and advanced TNM stage, and ESCC patients with a high- level of eIF3b expression have a shorter overall survival and disease-free survival than those with lower eIF3b expression (Fig.…”